Lymphoseek "effectively identifies" metastases in Phase II study
This article was originally published in Clinica
Executive Summary
A Phase II trial of Neoprobe's Lymphoseek has shown the cancer tracer to be safe and effective in lymphatic mapping.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.